Literature DB >> 28964839

In-silico screening and experimental validation reveal L-Adrenaline as anti-biofilm molecule against biofilm-associated protein (Bap) producing Acinetobacter baumannii.

Vishvanath Tiwari1, Varsha Patel2, Monalisa Tiwari2.   

Abstract

Acinetobacter baumannii, an ESKAPE pathogen, causes various nosocomial infections and has capacity to produce biofilm. Biofilm produced by this bacterium is highly tolerant to environmental factors and different antibiotics. Biofilm-associated protein (Bap) plays a significant role in the biofilm formation by A. baumannii and found in the extra cellular matrix of the biofilm. Therefore, it becomes essential to find a potential drug against Bap that has capacity to inhibit biofilm formation by A. baumannii. In-silico screening, molecular mechanics and molecular dynamics studies identified ZINC00039089 (L-Adrenaline) as an inhibitor for Bap of A. baumannii. Recently, it is reported that Bap can form amyloid like structure; hence we have created dimer of Bap protein. This inhibitor can bind to dimeric Bap with good affinity. It confirms that ZINC00039089 (L-Adrenaline) can bind with Bap monomer as well as oligomeric Bap, responsible for amyloid formation and biofilm formation. Hence, we have tested Adrenaline as an anti-biofilm molecule and determined its IC50 value against biofilm. The result showed Adrenaline has anti-biofilm activity with IC50 value of 75μg/ml. Therefore; our finding suggests that L-Adrenaline can be developed to inhibit biofilm formation by carbapenem resistant strain of Acinetobacter baumannii.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Anti-biofilm molecules; Bap protein; Biofilm; Carbapenem resistance

Mesh:

Substances:

Year:  2017        PMID: 28964839     DOI: 10.1016/j.ijbiomac.2017.09.105

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  8 in total

1.  Mechanism of Anti-bacterial Activity of Zinc Oxide Nanoparticle Against Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Vishvanath Tiwari; Neha Mishra; Keval Gadani; P S Solanki; N A Shah; Monalisa Tiwari
Journal:  Front Microbiol       Date:  2018-06-06       Impact factor: 5.640

2.  Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.

Authors:  Vishvanath Tiwari
Journal:  Int J Biol Macromol       Date:  2021-01-07       Impact factor: 6.953

Review 3.  Factors mediating Acinetobacter baumannii biofilm formation: Opportunities for developing therapeutics.

Authors:  Kirti Upmanyu; Qazi Mohd Rizwanul Haq; Ruchi Singh
Journal:  Curr Res Microb Sci       Date:  2022-03-28

4.  Interaction of Acinetobacter baumannii with Human Serum Albumin: Does the Host Determine the Outcome?

Authors:  Camila Pimentel; Casin Le; Marisel R Tuttobene; Tomas Subils; Krisztina M Papp-Wallace; Robert A Bonomo; Marcelo E Tolmasky; Maria Soledad Ramirez
Journal:  Antibiotics (Basel)       Date:  2021-07-08

5.  Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii.

Authors:  Vandana Solanki; Vishvanath Tiwari
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

Review 6.  Molecular insight into the therapeutic potential of phytoconstituents targeting protein conformation and their expression.

Authors:  Vishvanath Tiwari
Journal:  Phytomedicine       Date:  2018-09-26       Impact factor: 5.340

7.  Novel hybrid antiviral VTRRT-13V2.1 against SARS-CoV2 main protease: retro-combinatorial synthesis and molecular dynamics analysis.

Authors:  Vishvanath Tiwari
Journal:  Heliyon       Date:  2020-09-30

8.  De novo design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2.

Authors:  Vishvanath Tiwari
Journal:  Biol Open       Date:  2020-10-15       Impact factor: 2.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.